ZWZhenwei Wen

Zhenwei Wen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhenwei Wen has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • Chenwen Li

    Department of Dermatology, Henan Provincial People's Hospital, Henan University People's Hospital, Zhengzhou, China

    1 shared publication
  • Hanchen Liu

    Neurovascular Center, Changhai Hospital, Naval Medical University, Shanghai, China

    1 shared publication
  • He Li

    Neurovascular Center, Changhai Hospital, Naval Medical University, Shanghai, China

    1 shared publication
  • Hongjian Shen

    Neurovascular Center, Changhai Hospital, Naval Medical University, Shanghai, China

    1 shared publication
  • Hongye Xu

    Neurovascular Center, Changhai Hospital, Naval Medical University, Shanghai, China

    1 shared publication
  • Hongyu Ma

    Neurovascular Center, Changhai Hospital, Naval Medical University, Shanghai, China

    1 shared publication

Latest Publications

  • Association between different bilirubin subtypes and clinical outcomes in acute ischemic stroke patients undergoing mechanical thrombectomy: A retrospective cohort study

    by Hongye Xu, Lijun Wang, Li Xu, Xiaoxi Zhang, Hongyu Ma, Jianqiang Fan, Longjuan Yu, He Li, Hanchen Liu, Hongjian Shen, et al.

    The association between serum bilirubin levels and clinical outcomes in acute ischemic stroke (AIS) patients undergoing mechanical thrombectomy (MT) remains elusive, warranting further investigation. This retrospective cohort study encompassed 787 AIS patients who underwent MT between January 2018 and December 2022. Baseline serum levels of direct bilirubin (DBIL), indirect bilirubin (IBIL), and total bilirubin (TBIL) were documented. Adverse clinical outcomes comprised any intracranial hemorrhage (ICH) within 72 h, symptomatic intracranial hemorrhage, stroke-associated pneumonia (SAP), early neurological deterioration, 3-month poor functional outcome, and 3-month mortality. The findings revealed that DBIL and TBIL levels exhibited positive correlations with the incidence of SAP, ICH, and 3-month poor functional outcome. IBIL levels demonstrated a positive association with ICH occurrence. Notably, DBIL tends to exhibite superior predictive value for adverse outcomes compared to IBIL and TBIL. In conclusion, baseline serum bilirubin could as a potential biomarker for adverse clinical outcomes in AIS patients undergoing MT, pending further validation.


  • Open Access

    Multiomic Landscape Uncovers TRMT112 as a Central Driver of HPV‐Positive Head and Neck Squamous Cell Carcinoma

    by Tongnan Yin, Qian Guo, Zhenwei Wen, Yikun Guo, Chenwen Li, Zhongyu Qu

    Head and neck squamous cell carcinoma (HNSCC) ranks second among men and sixth globally, with a notable increase in HPV‐associated cases. However, the molecular underpinnings and immune landscape of HPV+ HNSCC remain incompletely understood. In this study, we first retrieved and harmonized single‐cell RNA sequencing (RNA‐Seq), bulk RNA‐Seq, and spatial transcriptomic profiles from public repositories. We then applied high‐dimensional weighted gene coexpression network analysis (hdWGCNA) and gene nonnegative matrix factorization (GeneNMF) to dissect HPV+ epithelial subpopulations, their extracellular matrix (ECM)–interacting ligand programs, and CXCL/complement immune circuits. Furthermore, we mapped the spatial niches of malignant and immune cells and constructed a consensus prognostic index using 101 machine learning algorithms. Our findings revealed transcriptionally distinct HPV+ epithelial clusters that activate viral oncogenesis, inflammatory pathways, and ECM‐sensing pathways. These cells communicate with stromal and immune compartments via CXCL axes and complement cascades, yet they are spatially segregated from lymphocytes. A high‐risk signature, identified as HPV‐related risk genes including TRMT112, stratified the TCGA‐HNSC and GSE65858 cohorts into patients with markedly worse 1‐, 2‐, and 3‐year survival rates (ROC–AUC 0.934, 0.968, and 0.973) and poor responses to immunotherapy. Notably, TRMT112 expression inversely correlated with cytotoxic T‐cell infiltration, mechanistically linking it to the formation of “cold” tumors. Our integrative analysis defines HPV‐driven epithelial subpopulations whose TRMT112‐enriched, immune‐excluded microenvironment contributes to therapeutic resistance, thus providing robust prognostic biomarkers and actionable targets for precision immunotherapy in HPV+ HNSCC.